You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bispecific T-Cell engager

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Glioma, Glioblastoma Trial in Durham (hEGFRvIII-CD3 (BRiTE), Activated Cell Therapy)

Not yet recruiting
  • Malignant Glioma
  • Glioblastoma
  • hEGFRvIII-CD3 (BRiTE)
  • Activated Cell Therapy
  • Durham, North Carolina
    Duke University Medical Center
Jun 24, 2022

Relapsed/Refractory AML Trial in United States (CLN-049)

Recruiting
  • Relapsed/Refractory AML
  • Tampa, Florida
  • +3 more
Dec 2, 2021

Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in Worldwide (acapatamab, Pembrolizumab, Etanercept)

Active, not recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Prostate Cancer
  • Campbell, California
  • +29 more
Dec 6, 2022

Metastatic Castration Resistant Prostate Cancer Trial in United States (LAVA-1207)

Recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • LAVA-1207
  • Tampa, Florida
  • +3 more
Nov 18, 2022

Neuroendocrine Prostate Cancer Trial in Worldwide (Tarlatamab)

Recruiting
  • Neuroendocrine Prostate Cancer
  • Phoenix, Arizona
  • +19 more
Aug 11, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

MUC17-positive Solid Tumors Trial in Worldwide (AMG 199)

Recruiting
  • MUC17-positive Solid Tumors
  • AMG 199
  • Duarte, California
  • +20 more
Feb 23, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Myelodysplastic Syndrome (MDS) Trial in United States (AMV564 14-Day CIV)

Completed
  • Myelodysplastic Syndrome (MDS)
  • AMV564 14-Day CIV
  • Duarte, California
  • +4 more
Oct 11, 2021

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Resistance to GNC-038 in Relapsed and Refractory Diffuse Large

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Apr 17, 2022

    Small Cell Lung Carcinoma, Neuroendocrine Tumors Trial (BI 764532)

    Not yet recruiting
    • Small Cell Lung Carcinoma
    • Neuroendocrine Neoplasms
    • BI 764532
    • (no location specified)
    May 22, 2023

    B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • +2 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin
    Apr 4, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

    Active, not recruiting
    • Extranodal NK/T Cell Lymphoma, Nasal Type
    • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
    • Guangdong, China
      Sun Yat-sen University Cancer Center
    Oct 10, 2022

    Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)

    Recruiting
    • Large B-cell Lymphoma
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Jul 21, 2022

    Small Cell Lung Cancer Trial (Tarlatamab)

    Available
    • Small Cell Lung Cancer
    • (no location specified)
    Sep 26, 2023

    CS1+ or BCMA+ Multiple Myeloma Trial in Wuhan (Conditioning chemo followed by CAR T cell infusion)

    Recruiting
    • CS1+ or BCMA+ Multiple Myeloma
    • Conditioning chemotherapy followed by CAR T cell infusion
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Feb 11, 2022

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
    • Los Angeles, California
    • +3 more
    Apr 12, 2023

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)

    Active, not recruiting
    • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
    • CD19-CD22 CAR-T cells
    • Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Aug 2, 2022

    Solid Tumors Trial in Nashville (CX-904)

    Recruiting
    • Solid Tumors
    • Nashville, Tennessee
      Sarah Cannon Research Institute, LLC
    May 19, 2022

    Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (AZD5863)

    Recruiting
    • Gastric Cancer
    • +3 more
    • Jacksonville, Florida
    • +16 more
    Aug 17, 2023

    POMES Syndrome, Relapsed and Refractory POMES Syndrome Trial in Shanghai (anti-CD19/BCMA CAR-T cells, Fludarabine,

    Active, not recruiting
    • POMES Syndrome
    • Relapsed and Refractory POMES Syndrome
    • anti-CD19/BCMA CAR-T cells
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    Aug 5, 2021